HC Wainwright Reiterates “Buy” Rating for Catalyst Pharmaceuticals (NASDAQ:CPRX)

HC Wainwright reiterated their buy rating on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) in a research report sent to investors on Friday,Benzinga reports. The brokerage currently has a $30.00 price target on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently weighed in on the company. Truist Financial upped their target price on Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Citigroup raised their target price on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Finally, StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $29.50.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ:CPRX opened at $23.93 on Friday. The company has a market capitalization of $2.85 billion, a P/E ratio of 20.28, a P/E/G ratio of 3.62 and a beta of 0.75. Catalyst Pharmaceuticals has a 1 year low of $12.27 and a 1 year high of $24.27. The business’s 50 day simple moving average is $20.74 and its 200 day simple moving average is $18.11.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, Director David S. Tierney sold 15,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total transaction of $301,500.00. Following the completion of the transaction, the director now owns 348,874 shares in the company, valued at approximately $7,012,367.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Catalyst Pharmaceuticals news, Director David S. Tierney sold 15,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total transaction of $301,500.00. Following the transaction, the director now owns 348,874 shares of the company’s stock, valued at $7,012,367.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Steve Miller sold 150,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the transaction, the insider now directly owns 675,124 shares in the company, valued at approximately $13,738,773.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 11.00% of the company’s stock.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC grew its stake in Catalyst Pharmaceuticals by 62.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 681 shares in the last quarter. nVerses Capital LLC bought a new position in Catalyst Pharmaceuticals in the third quarter valued at $50,000. CWM LLC increased its stake in Catalyst Pharmaceuticals by 686.5% in the second quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 3,549 shares during the last quarter. Meeder Asset Management Inc. bought a new position in Catalyst Pharmaceuticals in the second quarter valued at $70,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Catalyst Pharmaceuticals during the second quarter valued at about $153,000. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.